J4I Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€10.59M
Enterprise Value€18.19
Total Cash (Recent Filing)€1.72M
Total Debt (Recent Filing)€75.00K
Price to Earnings (P/E)―
Beta-2.08
Next Earnings
Jun 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding7,899,737,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt relative to equity reduces refinancing pressure and fixed financial obligations, giving Solvonis greater flexibility to manage its operations and allocate capital. This balance-sheet cushion can help the company withstand continued development challenges without the added burden of high leverage.
Positive Equity BaseA positive and expanding equity base provides a stronger solvency foundation than a deficit position and offers some capacity to absorb ongoing losses. Although returns remain negative, this capital cushion supports financial resilience over the next several quarters if losses do not accelerate.
Cash Burn Tracks Reported LossesOperating cash burn broadly matching reported losses suggests the company is not experiencing a materially larger cash drain from hidden working-capital or other reported factors. While cash generation remains weak, this alignment makes near-term cash needs somewhat more predictable for planning.
Bears Say
Persistent LossesRecurring operating and net losses indicate that the current business model has not yet demonstrated sustainable profitability. Continued losses can consume the equity cushion, constrain investment capacity, and increase dependence on future financing or operational improvement over the next several quarters.
Revenue CollapseRevenue falling effectively to zero removes the visible operating base needed to support durable scale and margin improvement. Without a meaningful and recurring revenue stream, the company has limited demonstrated ability to convert its activities into commercial growth or fund operations internally.
Negative Cash GenerationPersistent operating and free-cash-flow deficits mean the company continues to require cash rather than generating it from operations. The worsening 2025 free-cash-flow position increases funding needs and could gradually weaken the balance sheet if the deficit persists.
Solvonis Therapeutics News
J4I FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is €10.59M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Jun 30, 2027 which is in 274 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Apr 29, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 7,899,737,000 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in DE:J4I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry.
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―